Wu, Haiting
Cheng, Hong
Wang, Caili
Yao, Li
Qin, Shuguang
Zuo, Li
Hu, Zhao
Zhang, Chun
Wu, Yiqing
Hofherr, Alexis
Mohan, Katie
Rush, Stephen
Li, Xuemei
Clinical trials referenced in this document:
Documents that mention this clinical trial
Roxadustat and Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease: A Randomized, Open-Label, Phase 4 Study (ALTAI)
https://doi.org/10.1007/s12325-023-02741-5
Funding for this research was provided by:
FibroGen, Inc.
AstraZeneca
Article History
Received: 14 July 2023
Accepted: 15 November 2023
First Online: 27 January 2024
Declarations
:
: The sponsor was involved in the study design, collection, analysis, interpretation of data, and data checking of information provided in the manuscript. However, ultimate responsibility for opinions, conclusions, and data interpretation lies with the authors. Roxadustat was developed through collaboration between FibroGen, Inc., Astellas, and AstraZeneca. Haiting Wu, Hong Cheng, Caili Wang, LI Yao, Shuguang Qin, Li Zuo, Zhao Hu, Chun Zhang, and Xuemei Li, declare no conflicts of interest. Alexis Hofherr and Stephen Rush are employees of, and hold or may hold stock in, AstraZeneca. Katie Mohan is a contractor working on behalf of AstraZeneca and Yiging Wu, is an employee of FibroGen, Inc.
: All participants provided written informed consent prior to performance of any screening tests or assessments. This study was conducted in accordance with the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice Guidelines, and applicable local health and regulatory requirements. The final study protocol and informed consent form were approved by the applicable independent ethics committee or institutional review board for each site (protocol D5741C00002; approved July 13, 2021).